288083-60-3

Basic information

• Product Name: 6-dimethylcarbamoyl-nicotinic acid
• CAS NO: 288083-60-3
• Molecular Weight: 194.19
• Mol File: 288083-60-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 6-dimethylcarbamoyl-nicotinic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-dimethylcarbamoyl-nicotinic acid(288083-60-3)
• EPA Substance Registry System: 6-dimethylcarbamoyl-nicotinic acid(288083-60-3)

Safety Data

• Hazardous Substances Data: 288083-60-3(Hazardous Substances Data)

Usage

Main properties

1. Molecular formula: C10H12N2O4
2. Derivative of nicotinic acid
3. Contains a dimethylcarbamoyl group
4. Used as an intermediate in the synthesis of pharmaceuticals and agricultural chemicals
5. Acts as a chelating agent
6. Potential antioxidant and anti-inflammatory properties

Specific content

1. Name: 6-dimethylcarbamoyl-nicotinic acid
2. Alternate name: dimethylcarbamoyl nicotinic acid or CDMCNA
3. Molecular formula: C10H12N2O4
4. Derivative of: nicotinic acid
5. Group: contains a dimethylcarbamoyl group
6. Uses: intermediate in the synthesis of pharmaceuticals and agricultural chemicals
7. Function: acts as a chelating agent
8. Preparatory use: precursor in the preparation of other compounds
9. Additional properties: potential antioxidant and anti-inflammatory properties
10. Research findings: compound of interest for potential therapeutic applications

Upstream product

• 881-86-7 dimethyl 2,5-pyridine dicarboxylate 
• 17874-79-2 pyridine-2,5-dicarboxylic acid 5-methyl ester 
• 124-40-3 dimethyl amine 

Relevant articles and documents

Identification of critical process impurities and their impact on process research and development

The identification of low-level critical process impurities and degradants encountered during pharmaceutical development is crucial to the process development, but can often be challenging and can negatively impact the timeline of the developmental program. This is demonstrated during the early stage of process research and development of a Factor Xa inhibitor, the caprolactam 1. Details focusing on rapid identification of impurities in the active pharmaceutical ingredient (API), recognition of their root causes of formation, and the impact on process development are described.

INHIBITORS OF HISTONE DEACETYLASE

The invention relates to a series of compounds useful for inhibiting histone deacetylase (HDAC) enzymatic activity. The invention also provides a method for inhibiting histone descetylase in a cell using said compounds as well as a method for treating cell proliferative diseases and conditions using said HDAC inhibitors. Further, the invention provides pharmaceutical compositions comprising the HDAC inhibiting compounds and a pharmaceutically acceptable carrier.